1Luc G. Mechanisms of action of hypolipidemic agents,Therapie 2000 ; 55 (6) : 661 - 668.
2Chinetti G, Fruchart JC, Staeles B, Peroxisome prolifera-toractivated receptors(PPARs): nuclear receptors with functions in the vascular wall, Z Kardiol 2001;90 Suppl 3:125-132.
3Steinmez A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001 ; 109(4) :548- 559.
4Rubbins H B, Roins S J, Collins D, et al. Gemfibrozil for the second prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group,NEngl J Med 1999;341:410-418.
5Goa K L, Barradell L B, Plosker G L, Bezafibrate, and update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52(5) :725-753.
6Frick M H, Syvanne M, Nieminen M S, et al. Prevention of angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation 1997;96:2137-2143.
7Diabetes atherosclerosis Intervention Study Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Dlabetes atherosclerosis Intervention Study,a radomized studies. Lancet 2001 ; 357 : 905- 910.
8Orcards TJ. Dyslipoproteinmia and diabetes[J]. J End Metab Clin, 1990, 12(3) :361 - 362.
9Atger VA, Giral P, Simon A, et al. High-density lipoprotein subfractions as markers of early atherosclerosis[J]. Am J cardiol, 1995,75 : 127.
10Turner RC, Millns,Neil H,et al. For the united kingttom prospective diabetes study group. Risk factors for coronary artery disease in non-in-sulin dependent diabetes mellitus: united kinglom prospective diabetes study (UKPDS: 23) [J]. BMJ, 1998,316: 823.
